JP6395611B2 - チャネルロドプシン−２（Ｃｈｏｐ２）の変異の同定および使用法 - Google Patents

チャネルロドプシン−２（Ｃｈｏｐ２）の変異の同定および使用法 Download PDF

Info

Publication number
JP6395611B2
JP6395611B2 JP2014561051A JP2014561051A JP6395611B2 JP 6395611 B2 JP6395611 B2 JP 6395611B2 JP 2014561051 A JP2014561051 A JP 2014561051A JP 2014561051 A JP2014561051 A JP 2014561051A JP 6395611 B2 JP6395611 B2 JP 6395611B2
Authority
JP
Japan
Prior art keywords
cell
cells
chop2
seq
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014561051A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015510759A5 (enExample
JP2015510759A (ja
Inventor
ズオ−フア パン，
ズオ−フア パン，
Original Assignee
ウェイン・ステート・ユニバーシティー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ウェイン・ステート・ユニバーシティー filed Critical ウェイン・ステート・ユニバーシティー
Publication of JP2015510759A publication Critical patent/JP2015510759A/ja
Publication of JP2015510759A5 publication Critical patent/JP2015510759A5/ja
Application granted granted Critical
Publication of JP6395611B2 publication Critical patent/JP6395611B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/405—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from algae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2014561051A 2012-03-05 2013-03-05 チャネルロドプシン−２（Ｃｈｏｐ２）の変異の同定および使用法 Active JP6395611B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261606663P 2012-03-05 2012-03-05
US61/606,663 2012-03-05
PCT/US2013/029171 WO2013134295A1 (en) 2012-03-05 2013-03-05 Identification of channelrhodopsin-2 (chop2) mutations and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018082403A Division JP2018134098A (ja) 2012-03-05 2018-04-23 チャネルロドプシン−２（Ｃｈｏｐ２）の変異の同定および使用法

Publications (3)

Publication Number Publication Date
JP2015510759A JP2015510759A (ja) 2015-04-13
JP2015510759A5 JP2015510759A5 (enExample) 2016-04-28
JP6395611B2 true JP6395611B2 (ja) 2018-09-26

Family

ID=47892055

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2014561051A Active JP6395611B2 (ja) 2012-03-05 2013-03-05 チャネルロドプシン−２（Ｃｈｏｐ２）の変異の同定および使用法
JP2018082403A Withdrawn JP2018134098A (ja) 2012-03-05 2018-04-23 チャネルロドプシン−２（Ｃｈｏｐ２）の変異の同定および使用法
JP2019123061A Pending JP2019193656A (ja) 2012-03-05 2019-07-01 チャネルロドプシン−２（Ｃｈｏｐ２）の変異の同定および使用法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2018082403A Withdrawn JP2018134098A (ja) 2012-03-05 2018-04-23 チャネルロドプシン−２（Ｃｈｏｐ２）の変異の同定および使用法
JP2019123061A Pending JP2019193656A (ja) 2012-03-05 2019-07-01 チャネルロドプシン−２（Ｃｈｏｐ２）の変異の同定および使用法

Country Status (16)

Country Link
US (3) US10947281B2 (enExample)
EP (1) EP2822964B1 (enExample)
JP (3) JP6395611B2 (enExample)
KR (1) KR102137717B1 (enExample)
CN (2) CN104334575A (enExample)
AU (4) AU2013230112A1 (enExample)
CA (1) CA2866405A1 (enExample)
DK (1) DK2822964T3 (enExample)
EA (1) EA201491643A1 (enExample)
ES (1) ES2703324T3 (enExample)
HU (1) HUE040487T2 (enExample)
MX (1) MX360085B (enExample)
NZ (1) NZ629843A (enExample)
PL (1) PL2822964T3 (enExample)
PT (1) PT2822964T (enExample)
WO (1) WO2013134295A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2019588A4 (en) 2006-05-04 2010-11-24 Univ Wayne State RESTORATION OF VISUAL RESPONSES BY IN VIVO ADMINISTRATION OF NUCLEIC ACIDS OF RHODOPSIN
US9453241B2 (en) 2010-05-04 2016-09-27 Wayne State University AAV-mediated subcellular targeting of heterologous rhodopsins in retinal ganglion cells
CN104334575A (zh) * 2012-03-05 2015-02-04 韦恩州立大学 通道视蛋白-2(Chop2)突变的鉴定及使用方法
CA2903545C (en) 2013-03-14 2022-09-06 Wayne State University Method of enhancing delivery of therapeutic compounds to the eye
US10234761B2 (en) 2013-07-08 2019-03-19 Basf Se Oxime ester photoinitiators
EP3117002B1 (en) 2014-03-11 2025-12-03 Wayne State University A modified mglur6 promoter and methods of use
CA3022634A1 (en) 2016-05-03 2017-11-09 Wayne State University Method of enhancing viral-mediated gene delivery in the eye using proteosome inhibitors
US20190218256A1 (en) * 2016-06-03 2019-07-18 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Mutant light-inducible ion channel of channelrhodopsin
CN119979612A (zh) * 2016-08-29 2025-05-13 韦恩州立大学 在具有改善光敏感性的通道视蛋白变体中突变的识别及其使用方法
AU2017372351B2 (en) * 2016-11-06 2019-12-12 Nanoscope Technologies Llc Optogenetic modulation by multi-characteristic opsins for vision restoration and other applications thereof
CA3059652A1 (en) * 2017-04-12 2018-10-18 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. New optogenetic tool
KR102756155B1 (ko) * 2017-12-04 2025-01-20 라보라토리오스 에스에이엘브이에이티, 에스.에이. 도베실산을 포함하는 후안부 질환 치료를 위한 안과용 국소 조성물
JP6567153B1 (ja) * 2018-09-28 2019-08-28 学校法人東北工業大学 対象化合物の特性の予測を行うための方法、コンピュータシステム、プログラム
WO2024226667A2 (en) * 2023-04-24 2024-10-31 Nanoscope Therapeutics Inc. Optogenetic modulation by multi-characteristic opsins for vision restoration and other applications thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4498919A (en) 1983-10-31 1985-02-12 Corning Glass Works Method for making colored photochromic prescription ophthalmic lenses
US6610287B1 (en) 1990-04-16 2003-08-26 The General Hospital Corporation Transfer and expression of gene sequences into nervous system cells using herpes simplex virus mutants with deletions in genes for viral replication
US5827702A (en) 1994-10-31 1998-10-27 Genentech, Inc. Ocular gene therapy
CA2287495A1 (en) 1997-04-21 1998-10-29 University Of Florida Materials and methods for treatment of retinal diseases
AU775245B2 (en) 1998-09-17 2004-07-22 Catholic University Nijmegen Methods for treatment of degenerative retinal diseases
AU2001255575B2 (en) 2000-04-28 2006-08-31 The Trustees Of The University Of Pennsylvania Recombinant aav vectors with aav5 capsids and aav5 vectors pseudotyped in heterologous capsids
WO2002082904A2 (en) 2001-04-13 2002-10-24 The Trustees Of The University Of Pennsylvania Method of treating or retarding the development of blindness
US7144733B2 (en) 2001-08-16 2006-12-05 Sloan-Kettering Institute For Cancer Research Bio-synthetic photostimulators and methods of use
DE10216005A1 (de) 2002-04-11 2003-10-30 Max Planck Gesellschaft Verwendung von biologischen Photorezeptoren als direkt lichtgesteuerte Ionenkanäle
AU2003249318A1 (en) 2002-07-18 2004-02-09 The General Hospital Corp. Method for augmenting vision in persons suffering from photoreceptor cell degeneration
US7186699B2 (en) 2003-06-03 2007-03-06 Cell Genesys, Inc. Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes
WO2005044096A2 (en) 2003-11-05 2005-05-19 Neurovision, Inc. Method for improving visual perception
US8906360B2 (en) 2005-07-22 2014-12-09 The Board Of Trustees Of The Leland Stanford Junior University Light-activated cation channel and uses thereof
EP2019588A4 (en) 2006-05-04 2010-11-24 Univ Wayne State RESTORATION OF VISUAL RESPONSES BY IN VIVO ADMINISTRATION OF NUCLEIC ACIDS OF RHODOPSIN
US9453241B2 (en) 2010-05-04 2016-09-27 Wayne State University AAV-mediated subcellular targeting of heterologous rhodopsins in retinal ganglion cells
BR112013005634A2 (pt) * 2010-09-08 2017-06-27 Max Planck Gesellschaft canal-rodopsina 2 mutante
CN104334575A (zh) * 2012-03-05 2015-02-04 韦恩州立大学 通道视蛋白-2(Chop2)突变的鉴定及使用方法
KR101639859B1 (ko) 2014-03-06 2016-07-14 포항공과대학교 산학협력단 광 자극에 의한 미토콘드리아 활성의 시공간적 가역 조절 방법

Also Published As

Publication number Publication date
MX360085B (es) 2018-10-10
US20150044181A1 (en) 2015-02-12
AU2017239601A1 (en) 2017-10-26
PL2822964T3 (pl) 2019-05-31
US10947281B2 (en) 2021-03-16
CN104334575A (zh) 2015-02-04
AU2017239601B2 (en) 2019-05-16
EA201491643A1 (ru) 2015-02-27
EP2822964A1 (en) 2015-01-14
DK2822964T3 (en) 2018-12-10
EP2822964B1 (en) 2018-08-22
JP2019193656A (ja) 2019-11-07
PT2822964T (pt) 2018-11-29
JP2018134098A (ja) 2018-08-30
AU2019216638A1 (en) 2019-09-05
HK1205744A1 (en) 2015-12-24
MX2014010664A (es) 2015-03-06
KR20140132401A (ko) 2014-11-17
AU2013230112A1 (en) 2014-09-25
US20220033449A1 (en) 2022-02-03
HUE040487T2 (hu) 2019-03-28
KR102137717B1 (ko) 2020-07-27
AU2019216638B2 (en) 2021-07-08
CN111378020A (zh) 2020-07-07
CA2866405A1 (en) 2013-09-12
JP2015510759A (ja) 2015-04-13
WO2013134295A1 (en) 2013-09-12
AU2021245195B2 (en) 2023-09-28
AU2021245195A1 (en) 2021-11-04
NZ629843A (en) 2017-03-31
NZ727041A (en) 2022-01-28
US20250066431A1 (en) 2025-02-27
ES2703324T3 (es) 2019-03-08

Similar Documents

Publication Publication Date Title
JP6395611B2 (ja) チャネルロドプシン−２（Ｃｈｏｐ２）の変異の同定および使用法
JP6511066B2 (ja) 遺伝子治療を用いた網膜変性の処置
US20240165198A1 (en) Optogenetic visual restoration using chrimson
US20230159609A1 (en) G-protein-gated-k+ channel-mediated enhancements in light sensitivity in rod-cone dystrophy (rcd)
Batabyal et al. Multi-Characteristic Opsin Therapy to Functionalize Retina, Attenuate Retinal Degeneration, and Restore Vision in Mouse Models of Retinitis Pigmentosa
JP6779546B2 (ja) 視力回復のための多特性オプシンによる光遺伝学的調節及びその別の用途
EP3892738A1 (en) G-protein-gated-k+ channel-mediated enhancements in light sensitivity in rod-cone dystrophy (rcd)
HK1205744B (en) Identification of channelrhodopsin-2 (chop2) mutations and methods of use
US20230338581A1 (en) G-protein-gated-k+ channel-mediated enhancements in light sensitivity in rod-cone dystrophy (rcd)
EA043449B1 (ru) ИДЕНТИФИКАЦИЯ МУТАЦИЙ КАНАЛ-ОПСИНА-2 (Chop2) И СПОСОБЫ ПРИМЕНЕНИЯ
NZ727041B2 (en) Identification of channelrhodopsin-2 (chop2) mutations and methods of use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160304

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160304

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170119

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170131

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170427

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170629

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170731

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20171222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180423

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20180529

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180713

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180809

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180828

R150 Certificate of patent or registration of utility model

Ref document number: 6395611

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250